Today, Analysts' Corner announced new research reports highlighting Mylan Inc. (NASDAQ: MYL), UnitedHealth Group Inc. (NYSE: UNH), GlaxoSmithKline plc (ADR) (NYSE: GSK), Actavis Inc. (NYSE: ACT), and Mallinckrodt
plc (NYSE: MNK). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst
ratings - via the links below.
Mylan Inc. Research Report
On September 9, 2013, Mylan Inc.'s subsidiary Mylan Specialty L.P. (Mylan Specialty) announced that its Get Schooled in Anaphylaxis initiative has launched a new tool, a children's e-book narrated by Emmy-award winning actress Julie Bowen,
to help raise awareness and preparedness for life-threatening allergic
reactions or anaphylaxis. According to Mylan Specialty, the e-book,
titled The Adventures of Ana and Phyl: The Carnival, is designed
to assist parents and elementary school staff talk to kids about this
sometimes scary subject in a non-threatening way. According to the
Company, the e-book was partly inspired by the many submissions received
through the Get Schooled in Anaphylaxis Challenge Competition that
culminated earlier in 2013, and is dedicated to the 15 scholarship
winners and honors them by naming the characters after them. The Company
further stated that interested parties can get the e-book for free at
the Get Schooled in Anaphylaxis website. The Full Research Report on
Mylan Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a20_MYL]
--
UnitedHealth Group Inc. Research Report
On September 5, 2013,
UnitedHealth Group Inc. (UnitedHealth) announced that employees of
Arizona Diamondbacks have joined the Company to stuff backpacks with
food to support Kitchen on the Street's Bags of Hope Program, a childhood hunger program. According to the Company, both the organizations are working together to help Arizona-based nonprofit feed nearly 700 children in September 2013.
UnitedHealth added that the project is the latest "Do Good. Live Well."
employee volunteer initiative, whose mission is to prevent hunger and
obesity, inspire service, and encourage volunteerism in communities
where UnitedHealth employees live and work. Jeri Jones,
west region president, UnitedHealthcare Community & State, said,
"We are grateful for the opportunity to partner with the Diamondbacks
and Kitchen on the Street to help build a healthier community and
provide Phoenix-area
children access to nutritious food." The Full Research Report on
UnitedHealth Group Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]
--
GlaxoSmithKline plc (ADR) Research Report
On September 10, 2013,
GlaxoSmithKline plc (GSK) and Theravance Inc. (Theravance) announced
that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US
Food and Drug Administration (FDA) has recommended approval of
umeclidinium/vilanterol in US, for treating the patients with chronic
obstructive pulmonary disease (COPD), including bronchitis and
emphysema. The Company stated that majority of the advisory committee
members are of the opinion that the safety of the investigational
medicine has been adequately demonstrated at the 62.5/25mcg dose for the
proposed indication and the efficacy data provided substantial evidence
of a clinically meaningful benefit for UMEC/VI 62.5/25mcg once daily
for the long-term, maintenance treatment of airflow obstruction in COPD.
The Full Research Report on GlaxoSmithKline plc (ADR) - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]
--
Actavis Inc. Research Report
On September 10, 2013, Actavis Inc. (Actavis) and Warner Chilcott plc (Warner Chilcott) announced that shareholders of both the Companies have approved a proposal regarding Actavis' acquisition of Warner Chilcott. According to Actavis, the Company and Warner Chilcott's
shareholder approvals fulfills certain conditions for closing of the
transaction, which expected to occur early in Q4 2013, subject to
certain regulatory approvals, approval by the Irish High Court and the
customary closing conditions. The Full Research Report on Actavis Inc. -
including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]
--
Mallinckrodt plc Research Report
On September 5, 2013, Mallinckrodt plc (Mallinckrodt)
presented the results of its efficacy study on MNK-795 - its
investigational, extended-release oral formulation of oxycodone and
acetaminophen, at PAINWeek - a national conference on pain for frontline
practitioners, held in Las Vegas through September 4 to September 7, 2013.
According to the Company, investigational drug MNK-795 achieved the
primary endpoint in a Phase 3 efficacy trial in the treatment of acute
pain following bunionectomy. Mallinckrodt
stated that in the study, MNK-795 showed statistically significant
improvement in pain scores compared to placebo from baseline over 48
hours. Tom Smith, MD, Chief Medical Officer at Mallinckrodt,
said, "We are pleased that MNK-795 met the primary endpoint of the
study and we are excited to be able to share the clinical story for this
product by presenting these and other data at PAINWeek." The Full
Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/24f6_MNK]
source: prnewswire
No comments:
Post a Comment